Concerns are mounting for people who have been given Pfizer’s Paxlovid treatment regimen after contracting COVID-19, only to become positive for the infection once again after completing the treatment.
The U.S. Centers for Disease Control and Prevention (CDC) and other health officials have stepped in to clarify the rise in infections, issuing a warning for the unlucky patients who experience symptom recurrence after treatment with Paxlovid.
U.S. health officials have acknowledged reports of rising COVID-19 infections over the last month. From mid-April to mid-May, reports of new COVID-19 cases have jumped from 12,000 to almost 20,000. Death rates have remained stable during this rise.
Prior to the CDC’s announcement, the red flag had already been waved. At the beginning of May, 3CL Pharma Ltd., a Todos Medical Ltd. subsidiary, released data from a 30-day case study of a patient who had experienced COVID-19 rebound infection after taking a full course of Paxlovid. The data reported that the patient had severe symptom recurrence on the final day of the Paxlovid treatment regimen.
The U.S. Food and Drug Administration issued a statement several weeks ago about the medicinal intervention for recurrent infections. Clarification was given that a longer course of Paxlovid would provide no benefits to patients, regardless of recurrence or symptom rebound. The administration added that urgency has been given to addressing recurrent infection concerns.
